These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The effectiveness of so-called potentiated penicillins (augmentin and tazobactam) in vitro].
    Author: Blahová J, Hupková M, Krcméry V.
    Journal: Cas Lek Cesk; 1995 Sep 06; 134(17):558-61. PubMed ID: 7553760.
    Abstract:
    The resistance of bacterial strains to beta-lactam antibiotics (penicillins and cephalosporins) is due to transfer of genes coding the production of enzymes-beta-lactamases. These enzymes--penicillinases and cephalosporinases--can hydrolyse beta-lactam antibiotics. The using of beta-lactamase inhibitors in combination with some beta-lactam antibiotics is a suitable alternative in the present unfavourable situation in chemotherapy (increase of occurrence of gram-negative and gram-positive penicillin-cephalosporin-resistant bacterial strains). In this communication the authors present the review of efficiency of three, in clinical practice mostly used potentiated penicillins: Augmentin (amoxicillin + clavulanate), Unasyn (ampicillin + sulbactam) and Tazobac (piperacillin + tazobactam). Tazobactam seems to be the most promising beta-lactamase inhibitor which has, unlike clavulanate and sulbactam, its own antibiotic activity.
    [Abstract] [Full Text] [Related] [New Search]